Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
- Norman L. Letvin*,
- David C. Montefiori†,
- Yasuhiro Yasutomi*,‡,
- Helen C. Perry§,
- Mary-Ellen Davies§,
- Christine Lekutis*,
- Marianne Alroy*,
- Daniel C. Freed§,
- Carol I. Lord*,
- Laurence K. Handt§,
- Margaret A. Liu§, and
- John W. Shiver§
- *Harvard Medical School, Beth Israel Hospital, Boston, MA 02215; †Department of Surgery, Duke University Medical Center, Durham, NC 27710; and §Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA 19486
-
Communicated by Edward M. Scolnick, Merck & Co., Inc., West Point, PA (received for review January 27, 1997)
Abstract
It is generally thought that an effective vaccine to prevent HIV-1 infection should elicit both strong neutralizing antibody and cytotoxic T lymphocyte responses. We recently demonstrated that potent, boostable, long-lived HIV-1 envelope (Env)-specific cytotoxic T lymphocyte responses can be elicited in rhesus monkeys using plasmid-encoded HIV-1 env DNA as the immunogen. In the present study, we show that the addition of HIV-1 Env protein to this regimen as a boosting immunogen generates a high titer neutralizing antibody response in this nonhuman primate species. Moreover, we demonstrate in a pilot study that immunization with HIV-1 env DNA (multiple doses) followed by a final immunization with HIV-1 env DNA plus HIV-1 Env protein (env gene from HXBc2 clone of HIV IIIB; Env protein from parental HIV IIIB) completely protects monkeys from infection after i.v. challenge with a chimeric virus expressing HIV-1 env (HXBc2) on a simian immmunodeficiency virusmac backbone (SHIV-HXBc2). The potent immunity and protection seen in these pilot experiments suggest that a DNA prime/DNA plus protein boost regimen warrants active investigation as a vaccine strategy to prevent HIV-1 infection.
Footnotes
-
↵ † To whom reprint requests should be addressed.
-
↵ ‡ Present address: Mie University School of Medicine, Mie, Japan.
- ABBREVIATIONS:
- CTL,
- cytotoxic T lymphocyte;
- Env,
- envelope;
- PBMC,
- peripheral blood mononuclear cells;
- SIV,
- simian immunodeficiency virus;
- SHIV-HXBc2,
- chimeric HIV/SIV
- Copyright © 1997, The National Academy of Sciences of the USA





